Literature DB >> 2990494

A novel biologically active seleno-organic compound--V. Inhibition by ebselen (PZ 51) of rat peritoneal neutrophil lipoxygenase.

H Safayhi, G Tiegs, A Wendel.   

Abstract

Suspensions of rat peritoneal PMNLs elicited with glycogen were stimulated by calcium and an ionophore to produce leukotrienes from endogenous arachidonic acid. We investigated the effect of the non-toxic, anti-inflammatory seleno-organic compound, ebselen (PZ 51). When ethanolic extracts of the medium of stimulated cells were analysed by HPLC, a dose-dependent inhibition by ebselen of LTB4 formation with a concomitant decrease of 5-HETE production was found. Half-maximum inhibition was observed at 20 mumoles/l ebselen. Similar findings were obtained after analysis of chloroform extracts of both cells and medium using a different HPLC system. Under these conditions, enhanced 5-HETE formation was associated with reduced production of LTB4 and other di-HETE isomers, when purified glutathione peroxidase + GSH were present. We conclude that the reported GSH peroxidase-like activity of ebselen, catalysing the reduction of 5-HPETE to 5-HETE, can not account for our findings. Therefore, the lipoxygenase reaction itself apparently represents the site of inhibition of LTB4 formation by ebselen.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990494     DOI: 10.1016/0006-2952(85)90569-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

Review 1.  The pharmacology of ebselen.

Authors:  M J Parnham; S Leyck; E Graf; E J Dowling; D R Blake
Journal:  Agents Actions       Date:  1991-01

2.  Neuroprotective effects of ebselen on experimental spinal cord injury in rats.

Authors:  Murat Kalayci; Omer Coskun; Ferda Cagavi; Mehmet Kanter; Ferah Armutcu; Sanser Gul; Bektas Acikgoz
Journal:  Neurochem Res       Date:  2005-03       Impact factor: 3.996

3.  Acute antiinflammatory and gastric effects of the seleno-organic compound ebselen.

Authors:  S Leyck; M J Parnham
Journal:  Agents Actions       Date:  1990-06

4.  Proceedings of the British Pharmacological Society. 18th-20th December 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

Review 5.  Antioxidants as potential therapeutics for lung fibrosis.

Authors:  Brian J Day
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

6.  Induction of inflammatory cell infiltration and necrosis in normal mouse skin by the combined treatment of tumor necrosis factor and lithium chloride.

Authors:  R Beyaert; C De Potter; B Vanhaesebroeck; F Van Roy; W Fiers
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

7.  Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity.

Authors:  E R Sailer; L R Subramanian; B Rall; R F Hoernlein; H P Ammon; H Safayhi
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

8.  Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells.

Authors:  Masanori Yoshizumi; Toshiaki Kogame; Yuki Suzaki; Yoshiko Fujita; Moe Kyaw; Kazuyoshi Kirima; Keisuke Ishizawa; Koichiro Tsuchiya; Shoji Kagami; Toshiaki Tamaki
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

9.  Catalase and glutathione peroxidase mimics.

Authors:  Brian J Day
Journal:  Biochem Pharmacol       Date:  2008-10-01       Impact factor: 5.858

10.  The anti-inflammatory activity of Ebselen but not thiols in experimental alveolitis and bronchiolitis.

Authors:  I A Cotgreave; U Johansson; G Westergren; P W Moldéus; R Brattsand
Journal:  Agents Actions       Date:  1988-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.